Home
Join A Case
Contact
More
Class Action Cases
Bristol-Myers Squibb Company
According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) that Bristol-Myers’ CheckMate-026 trial was more likely to fail than Defendants were representing; (2) that Bristol- Myers’ CheckMate-026 trial failed more severely than the Company indicated it did in the Company’s August 5, 2016 announcements and disclosures; and (3) that, as a result of the foregoing, Defendants’ statements about Bristol-Myers’ business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the truth was revealed to the investing public, shares dropped causing shareholders harm.
Press Release
Case has been filed